Opinion|Videos|March 25, 2025

Navigating Cost Considerations in Treatment Selection of mCRC Agents

Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.

Video content above is prompted by the following:

  • What are the key payer-related challenges (eg, step edits, prior authorizations) that impact access to third-line therapies for patients with mCRC?
  • How do payer requirements influence treatment sequencing and decision-making in the third-line setting?
  • How do the costs associated with adverse events across the different third-line treatments (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab) influence treatment selection?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo